piscidin1 (2242) (tfa)

Piscidin-1 (22-42) (TFA) is a highly potent, multi-functional Antimicrobial Peptide (AMP) produced by Orange-spotted grouper (Epinephelus coioides).

Pam3CSK4 TFA (Pam3Cys-Ser-(Lys)4 TFA) is an agonist of toll-like receptor 1 2 (TLR1 2) (EC50 of 0.47 ng mL for human TLR1 2).

Rotigaptide TFA(355151-12-1 free base) is a novel and specific modulator of Cx43 and is a potent AAP. Rotigaptide TFA(355151-12-1 free base) prevents the uncoupling of Cx43-mediated gap junction communication and normalizes cell-to-cell communication during acute metabolic stress.

Jagged-1 (188-204) TFA(219127-21-6 free base) is a fragment of the JAG-1 protein. JAG-1 is Notch ligand, a peptide that is the most conspicuously expressed ligand in skin. JAG-1 induces epidermal maturation. Exposing submerged keratinocytes monolayers to JAG-1 with elevated calcium concentration produces stratification with loricrin expression and NF-alphaB activation.

pro-asp TFA(85227-98-1 free base) (TLβ4) down-regulate skin inflammation in mouse skin.

JAG-1, scrambled TFA is a scrambled sequence of JAG-1(188-204).

Angiotensin 1/2 (1-9)TFA is containing the amino acids 1-9 that are converted from Angiotensin I/II peptide.

Nociceptin (1-13), amide is a potent agonist Opioid receptor-like1 (ORL1) receptor with a pEC50 of 7.9 for mouse vas deferens and a Ki of 0.75 nM for binding to rat forebrain membranes.

Biotin-β-Amyloid (1-42), human TFA, also known as Biotin-Amyloid β-Peptide (1-42) (human) TFA, is a biotin-labeled 42-amino acid peptide implicated in the pathogenesis of Alzheimer's disease.

740 Y-P(TFA)(1236188-16-1 free base) (740YPDGFR(TFA)) is a potent and cell-permeable activator of PI3K.

Interphotoreceptor retinoid-binding protein (1-20) (IRBP1-20), a dodecapeptide fragment of retinoid-binding protein 3, plays a crucial role in pigment regeneration by facilitating the transport of retinol and retinal between photoreceptor cells and the retinal pigment epithelium. It has been utilized to provoke autoimmune uveoretinitis in C57BL/6 mice, possessing the H-2b haplotype. Furthermore, IRBP1-20 at a concentration of 3 µM enhances the secretion of IL-4, IL-5, and IL-6 from primary mouse spleen lymphocytes. Immunization and subsequent rechallenge with IRBP1-20 lead to increased ear swelling, inflammation of ocular blood vessels, infiltration by immune cells, damage to the photoreceptor layer, and retinal detachment in IFN-γ-deficient mice.

Gastric inhibitory peptide 1 (GIP-1) (3-42), a fragment of the incretin hormone GIP and antagonist to the GIP receptor, is generated through the action of serum dipeptidyl peptidase 4 (DDP-4). When administered at 25 nmol/kg to an ob/ob mouse diabetes model, GIP-1 (3-42) elevates plasma glucose levels and lowers plasma insulin levels, demonstrating its effect on reducing insulin secretion from BRIN-BD11 pancreatic cells at a concentration of 100 nM.

Super-tdu (1-31) TFA is an endogenous ligand of heptapeptide receptor and has a strong anti-analgesic effect.

Calcitonin Gene Related Peptide (CGRP) II, rat (TFA) is a neuropeptide with 37 amino acid.

ACTH (1-14) (TFA) is a polypeptide of corticotrophin, which promotes the release of cortisol.

This is a hypoxia-inducible factor-1 (HIF-1 a) 19-mer fragment. HIF-1 functions as master regulator of response to oxygen homeostasis. Hypoxia-induced gene expression is initiated when HIF-1 subunit is stabilized in response to a lack of oxygen. This part

MART-1 (26-35) (human) TFA is an amino acid residue of 26-35 protein.

TAT-DEF-Elk-1 TFA is a cell-penetrating peptide Elk-1 inhibitor, mimics and specifically interferes with the DEF domain of Elk-1. TAT-DEF-Elk-1 blocks Elk-1 phosphorylation and prevents Elk-1 nuclear translocation without interfering with ERK nor MSK1 act

Substance P(1-7) TFA, a fragment of the neuropeptide substance P (SP), induces depressor and bradycardic effects upon application to the nucleus tractus solitarius [1].

GLP-1(32-36)amide TFA, a pentapeptide derived from the C-terminal end of the glucoregulatory hormone GLP-1, has demonstrated the ability to mitigate weight gain and regulate glucose metabolism in diabetic mice [1] [2].

Grb2 SH2 Domain Inhibitor 1 TFA is a cyclic cell-penetrating peptide (CPP) featuring a conformationally restricted d-pro-l-pro motif ring (AF Φ Rpprrfq), where Φ represents L-naphthylalanine, R signifies D-arginine, and P stands for D-proline. It primarily functions as a cyclic peptide inhibitor.

Orexin B, human (TFA) is an endogenous agonist at Orexin receptor with Kis of 420 and 36 nM for OX1 and OX2.

A8SGLP-1 TFA, an orally active GLP-1 analogue, features a serine substitution for alanine at position 8. This compound effectively lowers blood glucose in db/db mice, maintaining its function [1].

TAT TFA (YGRKKRRQRRR) is derived from human immunodeficiency virus (hiv-1) transcription reverse activator TAT, is a cell penetrating peptide.

NEP(1-40) TFA is a peptide antagonist of the Nogo-66 receptor (NgR), which attenuates myelin-derived inhibition and mitigates injury-induced shifts in microglial morphology distributions [1].

HPV16 E7 (86-93) TFA is a human leukocyte antigen (HLA)-A2.1 restricted HPV16 E7-derived peptide.

ACTH (1-17) TFA, an analogue of adrenocorticotropin, is a potent agonist for the human melanocortin 1 (MC1) receptor with a dissociation constant (K i) of 0.21 nM.

LyP-1 TFA, a cyclic nine-amino-acid peptide, exhibits selective binding to p32 receptors, which are overexpressed in a variety of tumor-associated cells [1].

Glucagon-like peptide 1 (1-37), human (TFA), is a highly potent agonist of the GLP-1 receptor and is a pancreatic hormone synthesized through post-translational processing of proglucagon.

FSL-1 TFA, a toll-like receptor 2/6 (TLR2/6) agonist derived from bacteria, bolsters resistance against experimental HSV-2 infection[1] and stimulates MMP-9 production via the TLR2 and NF-κB/AP-1 signaling pathways in monocytic THP-1 cells[2].

HCV-1 e2 Protein (554-569) TFA, an antigenic segment of the hepatitis C virus envelope 2 (e2) protein, contains a potential N-glycosylation site that may influence immune recognition of e2 [1].

Dynorphin A (1-10) (TFA), an endogenous opioid neuropeptide, interacts with the extracellular loop 2 of the κ-opioid receptor and inhibits NMDA-activated currents with an IC50 of 42.0 μM.

Dynorphin B (1-13), a 13 amino acid, is an extraordinarily potent opioid peptide.

PAR 4 (1-6) TFA (GYPGQV TFA), a hexapeptide derived from protease-activated receptor 4 (PAR 4), serves as a specific agonist for PAR 4, exhibiting targeted activation properties.

K-(D-1-Nal)-FwLL-NH2 TFA is a potent, high-affinity inverse agonist of the ghrelin receptor with Ki values of 4.9 nM in COS7 cells and 31 nM in HEK293T cells, effectively inhibiting ghrelin receptor-mediated Gq- and G13-dependent signaling pathways.

LSKL, Inhibitor of Thrombospondin (TSP-1) TFA, a tetrapeptide derived from latency-associated protein (LAP)-TGFβ, acts as a competitive antagonist of TGF-β1.

Parathyroid Hormone (1-34), bovine TFA, a potent agonist of the parathyroid hormone (PTH) receptor, elevates calcium and inorganic phosphate levels in vivo and is used in osteoporosis research [1].

Hepcidin-1 (mouse) TFA, an endogenous peptide hormone, regulates iron homeostasis by upregulating mRNA levels of TRAP, cathepsin K, and MMP-9, enhancing TRAP-5b protein secretion, and downregulating FPN1 protein levels, thereby increasing intracellular iron. It also promotes osteoclast differentiation [1].

Gastric inhibitory peptide (GIP) (1-42), an endogenous incretin hormone comprising 42 amino acids, promotes insulin secretion. Expressed in the intestinal neuroendocrine K cells and submandibular gland, it enters circulation after meals. GIP (1-42) blocks histamine, pentagastrin, and insulin-induced gastric acid and pepsin secretion, enhances glucose-stimulated insulin release, and accelerates gastric emptying in rats.

LXW7 TFA, a cyclic peptide containing Arg-Gly-Asp (RGD), is an integrin αvβ3 inhibitor with an anti-inflammatory effect. LXW7 has a high binding affinity to αvβ3 integrin (IC50: 0.68 μM). It increases the phosphorylation of VEGFR-2 and activation of ERK1/2.

TAT-amide TFA is a cell penetrating peptide. The cell - penetrating peptides (CPPs) is a kind of access to the short amino acid sequence of different cells.

β-Amyloid (1-42), rat TFA is a 42-aa peptide, shows the effects of cytotoxicity on acute hippocampal slices, and has been used in studies of alzheimer's disease.

RGD peptide (GRGDNP) (TFA) promote apoptosis through activation of conformation changes that enhance pro-caspase-3 activation and autoprocessing.

Protease-Activated Receptor-3 (PAR-3) (1-6), human TFA, is a peptide that acts as an agonist for the proteinase-activated receptor (PAR-3) [1].

RFRP-1(human) TFA, an endogenous NPFF receptor agonist, exhibits potent activity with EC50 values of 0.0011 nM for NPFF2 and 29 nM for NPFF1. It significantly diminishes the contractile function of isolated rat and rabbit cardiac myocytes. Moreover, it decreases heart rate, stroke volume, ejection fraction, and cardiac output, while elevating plasma prolactin levels in rats.

Galanin (1-29)(rat, mouse) TFA acts as a non-selective agonist for galanin receptors, exhibiting affinities (Kis) of 0.98 nM for GAL1, 1.48 nM for GAL2, and 1.47 nM for GAL3, respectively, and possesses an anticonvulsant effect [1] [2].

IGF-I (30-41) (TFA) is amino acids 30 to 41 fragment of Insulin-like Growth Factor I (IGF-I).

YAP-TEAD-IN-1 TFA, a competitive inhibitor of the YAP–TEAD interaction (IC50: 25 nM), exhibits higher binding affinity to TEAD1 (Kd: 15 nM) compared to YAP (50-171) (Kd: 40 nM).

Atrial Natriuretic Peptide (ANP) (1-28), rat (TFA), is the primary circulating form of ANP in rats and significantly inhibits Ang II-stimulated secretion of endothelin-1.

iRGD Peptide 1 TFA is a prototypic tumor-homing peptide with tissue-penetrating capabilities, facilitating deep delivery of therapeutic agents into extravascular tumor tissue. Additionally, it possesses anti-metastatic activity [1].